期刊文献+

英夫利西单抗治疗重度银屑病17例临床观察 被引量:5

原文传递
导出
摘要 研究发现,肿瘤坏死因子a(TNF-a)在银屑病的发病中起重要作用。近年来,生物制剂在中、重度银屑病尤其既往治疗中疗效不佳的银屑病患者中应用日益广泛。英夫利西单抗(IFX)是一种人鼠嵌合性抗TNF—a单克隆抗体,美国FDA在2006年批准该药用于治疗银屑病。现将我科自2013年12月以来应用IFX治疗的17例银屑病患者情况报道如下。
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2016年第4期294-295,共2页 Chinese Journal of Dermatology
  • 相关文献

参考文献10

  • 1Gottlieb AB, Chamian F, Masud S, et down-regulates muhiple proinflammatow pathways in psoriasis plaques [ J. ] Immunol, 2005, 175 (4): 2721-2729. DOI: l 0.4049/ jimmunol. 175.4.2721.
  • 2Kimber 1, Cumberbatch M, Dearman RJ, et al. Cytokines and chenmkines in the initiation anti regulation of epidermal Langerhans cell mobilization [J ]. Br J Demlatol. 2000, 142 ( 3 ): 401-412. DOI: 10.1046/j.1365-2133.2000.03349.x.
  • 3Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis [J ]. Br J Dermatol, 2010, 162 (6): 1349-1358. DOI: 10.1111/j.1365- 2133.2010.09707.x.
  • 4Ahmad K, Rogers S. Three years' experience with infliximab in recalcitrant psoriasis[J]. Clin Exp Dermatol, 2006, 31 ( 5 ): 630- 633. DOI: 10.111 l/j.1365-2230.2006.02170.x.
  • 5Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referr',d centre [J ]. Br J Dennatol, 2009, 160 (1): 162-169. DOI: 10.1111/j.1365- 2133.2008.08865.x.
  • 6余晓玲,晋红中.英夫利西单抗治疗关节病性银屑病进展[J].中华皮肤科杂志,2014,47(3):223-225. 被引量:3
  • 7Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis[J]. J Am Aead Dermatol, 2007, 56( 1 ): 31. DOI: 10.1016/ j.jaad.2006.07.017.
  • 8张堂德,李琳琳,罗妙璇.英夫利西单抗治疗寻常性银屑病七例[J].中华皮肤科杂志,2015,48(6):438-439. 被引量:3
  • 9Fahroni C, Gori A, Troiano M, et al. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients [J]. J Eur Acad Demlatol Venereol, 2011, 25 (5): 549-553. DOI: 10.1111/j.1468- 3083.2010.03826.x.
  • 10G6mez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection [J]. Arthritis Rheum, 2007, 57 (5): 756-761. DOI: 10.1002/art.22768.

二级参考文献19

  • 1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3059
  • 2Vilma VS,de Carvalho JF,de Moraes JC. Autoantibodies in patients with psoriatic arthritis on anti-TNFa therapy[J].Revista Brasileira de Reumatologia,2010,(03):225-234.
  • 3Antoni CE,Kavanaugh A,Kirkham B. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis[J].Arthritis and Rheumatism,2005,(04):1227-1236.
  • 4Antoni CE,Kavanaugh A,Van der Heijde D. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis:findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)[J].Journal of Rheumatology,2008,(05):869-876.
  • 5Smolen JS,Emery P. Infliximab:12 years of experience[J].Arthritis Research and Therapy,2011,(Suppl 1):1-18.
  • 6Voulgari PV,Venetsanopoulou AI,Exarchou SA. Sustained clinical response and high infliximab survival in psoriatic arthritis patients:a 3-year long-term study[J].Seminars in Arthritis and Rheumatism,2008,(05):293-298.
  • 7Di Renzo L,Saraceno R,Schipani C. Why 3 mg/kg instead of 5 mg/kg of infliximab should work in psoriatic arthritis[J].Journal of Dermatology,2009,(12):666-668.
  • 8Alstergren P,Larsson PT,Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis[J].Scandinavian Journal of Rheumatology,2008,(02):155-157.
  • 9Conti F,Ceccarelli F,Priori R. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids.Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha[J].Annals of the Rheumatic Diseases,2008,(12):1787-1790.
  • 10Antoni C,Krueger GG,de Vlam K. Infliximab improves signs and symptoms of psoriatic arthritis:results of the IMPACT 2 trial[J].Annals of the Rheumatic Diseases,2005,(08):1150-1157.

共引文献3

同被引文献20

  • 1Schrn MP, Boehncke WH. Psoriasis[J]. N Engl J Med, 2005, 352 (18): 1899-1912. DOI: 10.1056/NEJMra041320.
  • 2Luber AJ, Tsui CL, Heinecke GM, et al. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis [J]. J Am Acad Dermatol, 2014, 70 (3): 525-532. DOI: 10.1016/j.jaad. 2013.10.059.
  • 3Dotan I, Ran Y, Yanai H, et al. Patient factors that increase infli- ximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study [J]. Inflamm Bowel Dis, 2014, 20 (12): 2247-2259. DOI: 10.1097/MIB. 0000000000000212.
  • 4Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double- blind, placebo-controlled trial [J]. J Am Acad Dermatol, 2004, 51 (4): 534-542. DOI: 10.1016/j.jaad.2004.02.021.
  • 5Wetter DA, Davis MD. Lupus-like syndrome attributable to anti- tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic [ J ]. Mayo Clin Proc, 2009, 84 ( 11 ): 979-984. DOI: 10.4065/84.11.979.
  • 6Zhu Chenyu, Sun Qiuning, Shu Chang, et al. Infliximab for the treatment of severe psoriasis in 17 cases: a clinical observational study[J]. Chin J Dermatol, 2016, 49(4): 294-295. DOI: 10.3760/ ema.j .issn.0412-4030.2016.04.021.
  • 7丁晓岚,王婷琳,沈佚葳,王晓艳,周城,田珊,刘盈,彭光辉,周俊娥,薛树旗,王仁利,唐英,孟雪梅,裴广德,白云花,刘青,李航,张建中.中国六省市银屑病流行病学调查[J].中国皮肤性病学杂志,2010,24(7):598-601. 被引量:347
  • 8刘伦飞,郑敏.英夫利西单抗在银屑病中的应用进展[J].中华皮肤科杂志,2013,46(3):216-219. 被引量:6
  • 9余晓玲,晋红中.英夫利西单抗治疗关节病性银屑病进展[J].中华皮肤科杂志,2014,47(3):223-225. 被引量:3
  • 10王聪敏,李海涛,余明莲,赵志力,徐晓敏,袁越.心理护理对银屑病患者心理状态的影响[J].实用皮肤病学杂志,2014,7(2):138-139. 被引量:20

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部